Clovis Oncology (CLVS) Misses Q4 EPS by 10c

Clovis Oncology (NASDAQ: CLVS) reported Q4 EPS of ($1.81), $0.10 worse than the analyst estimate of ($1.71). Revenue for the quarter came in at $39.3 million versus the consensus estimate of $38.97 million.

$296.7M in cash, cash equivalents and available for sale securities at December 31, 2019; continue to anticipate cash runway into 2H 2021.

“This is an encouraging time for Clovis, as we launch Rubraca in multiple European countries in the recurrent ovarian cancer maintenance indication and prepare for a potential U.S. approval and launch of Rubraca in patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer,” said Patrick J. Mahaffy, CEO and President of Clovis Oncology. “We also look forward to initial clinical data from lucitanib combination studies later this year, and initiating clinical development with FAP-2286, our peptide-targeted radiopharmaceutical therapy product candidate. This program, as well as our ongoing discovery collaboration with 3B Pharmaceuticals, provides us an exciting opportunity to be a leader in an important new area of oncology drug development.”

For earnings history and earnings-related data on Clovis Oncology (CLVS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c